Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY26 results · Apr–Jun 2025
Aarti Drugs reported revenue from operations of ₹590.51 crore (up 6.3% from Q1 FY25) and net profit of ₹53.97 crore (up 62.2% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 590.51 | 555.34 | +6.3% | 676.76 | −12.7% |
| Other income | 0.31 | 1.11 | −72.1% | 1.87 | −83.4% |
| Total income | 590.82 | 556.45 | +6.2% | 678.63 | −12.9% |
| Profit before tax | 51.11 | 43.98 | +16.2% | 71.15 | −28.2% |
| Net profit for the period | 53.97 | 33.27 | +62.2% | 62.77 | −14.0% |
| Attributable to shareholders of the company | 53.91 | 33.24 | +62.2% | 62.86 | −14.2% |
| EPS, basic (₹) | 5.91 | 3.62 | +63.3% | 6.88 | −14.1% |
| Net margin (%) | 9.1 | 6.0 | 9.3 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 520.96 | 492.96 | +5.7% | 622.96 | −16.4% |
| Other income | 0.38 | 0.11 | +245.5% | 1.71 | −77.8% |
| Total income | 521.34 | 493.07 | +5.7% | 624.67 | −16.5% |
| Profit before tax | 45.25 | 35.16 | +28.7% | 70.67 | −36.0% |
| Net profit for the period | 48.64 | 26.91 | +80.8% | 61.48 | −20.9% |
| EPS, basic (₹) | 5.33 | 2.93 | +81.9% | 6.74 | −20.9% |
| Net margin (%) | 9.3 | 5.5 | 9.9 |
Consolidated
- Filed with BSE
- 18 Jul 2025, 18:14 IST
- Board meeting
- 18 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 18 Jul 2025, 18:14 IST
- Board meeting
- 18 Jul 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Audited
- Source
- XBRL filing on BSE